Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis | Zendy

S J Veldhuyzen van Zanten | Zendy; C. W. McCormick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis

Author(s) -

S J Veldhuyzen van Zanten,

C. W. McCormick

Publication year - 1996

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/1996/894752

Subject(s) - ticlopidine , medicine , contraindication , anti nuclear antibody , jaundice , hepatitis , stroke (engine) , gastroenterology , anesthesia , antibody , immunology , autoantibody , pathology , myocardial infarction , mechanical engineering , alternative medicine , engineering , clopidogrel

Ticlopidine hydrochloride has been shown to reduce the risk of first or recurrent stroke in patients who have experienced a transient ischemic attack, reversible ischemic neurological deficit, recurrent stroke or first stroke. Severe liver dysfunction is a contraindication for its use. Increase in liver enzymes has been reported with use of this drug, but jaundice is rare. A case of severe ticlopidine-induced hepatitis that was associated with a marked increase in antinuclear antibody (ANA) levels is reported. Physicians prescribing ticlopidine hydrochloride should be aware that a potentially severe acute hepatitis associated with ANA positivity can occur. The drug should be discontinued if signs of liver dysfunction occur

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research